FDA review: Long-acting asthma drugs pose serious risks

12/7/2008 | NYTimes.com · Reuters

The FDA should revoke clearance for asthma drugs known as long-acting beta agonists for children in light of clinical evidence linking them to a higher risk of asthma attacks and death, according to a review from the agency's drug-safety personnel. The FDA plans to gather a panel of outside experts this week to evaluate the safety of AstraZeneca's Symbicort, Novartis AG's Foradil and GlaxoSmithKline's Advair and Serevent.

View Full Article in:

NYTimes.com · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC